Evidence map›Paper›PMID 33818732›Full record

ReviewCurrent osteoporosis reports2021

Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease.

Manish Adhikari, Jesús Delgado-Calle

Abstract readReview
In one paragraph

Review in Current osteoporosis reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Manish AdhikariDepartment of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Jesús Delgado-CalleDepartment of Physiology and Cell Biology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. jdelgadocalle@uams.edu.

Funding

Understanding the Negative Prognostic Impact of Intraosseous Focal Lesions in Multiple MyelomaP20GM125503 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI CHARLES A O'BRIEN · 2018 to 2026
$23.0M
Contribution of Osteocytes to the Musculoskeletal Effects of Multiple MyelomaR01CA209882 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI Teresita M. Bellido, Jesus Delgado-Calle · 2017 to 2026
$3.8M
Bone-Targeted Therapies to Improve Bone Health and Prevent Relapse in Multiple MyelomaR37CA251763 · NCI · UNIV OF ARKANSAS FOR MED SCIS · PI DELGADO-CALLE, JESUS · 2020 to 2025
$2.6M
Manipulating the N-end Rule Protein Degradation Pathway to Build Bone and Decrease Tumor Growth in Multiple Myeloma Bone DiseaseR01CA241677 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI CHIRGWIN, JOHN M · 2020 to 2024
$1.6M
NCI NIH HHS R01 CA209882NCI NIH HHS R01 CA241677NCI NIH HHS R37 CA251763NIGMS NIH HHS P20 GM125503
6 · The paper itself

Abstract

purpose of reviewThe goal of this manuscript is to review the current knowledge on the role of osteocytes in cancer in the bone, discuss the potential of osteocytes as a therapeutic target, and propose future research needed to understand the crosstalk between cancer cells and osteocytes in the tumor niche. RECENT

findingsNumerous studies have established that cancer cells manipulate osteocytes to facilitate invasion and tumor progression in bone. Moreover, cancer cells dysregulate osteocyte function to disrupt physiological bone remodeling, leading to the development of bone disease. Targeting osteocytes and their derived factors has proven to effectively interfere with the progression of cancer in the bone and the associated bone disease. Osteocytes communicate with cancer cells and are also part of the vicious cycle of cancer in the bone. Additional studies investigating the role of osteocytes on metastases to the bone and the development of drug resistance are needed.

Indexed as

AnimalsBone DiseasesBone RemodelingDisease ProgressionHumansNeoplasm InvasivenessOsteocytesSignal TransductionBoneBreast cancerCancerMyelomaOsteocytes

Identifiers

PMID33818732
PMCPMC8486016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.